A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

NCT02734693 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG: dasotraline 4mg
OTHER: Placebo

Sponsor

Sumitomo Pharma America, Inc.